Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 1037

Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China

Dr Heng Mei speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about improving the safety of CAR T-cell therapy by controlling CRS-related coagulopathy.

He reports that the phase I study found that early and proper interventions targeted at CRS-related coagulopathy are important in controlling side effects with the therapy.

Dr Mei says that the next steps for the study are to include more patients and to do multiple-centre research, potentially with collaborators from Europe.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation